{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007341","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.542905+00:00","generated_at":"2026-06-18T05:17:31.253262+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"aTyr Pharma holds less than 2% of cash at failed SVB; exposure limited","bullets":["As of March 10, 2023, aTyr holds less than 2% of cash equivalents and investments at SVB.","Company acknowledges SVB closure and FDIC receivership in SEC filing.","Remaining >98% of cash is held at other institutions, minimizing direct risk.","No material financial or operational impact anticipated from SVB failure.","Disclosure made under Regulation FD on March 10, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007341","json":"https://secwatch.observer/filing/0000950170-23-007341.json","markdown":"https://secwatch.observer/filing/0000950170-23-007341.md","text":"https://secwatch.observer/filing/0000950170-23-007341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023007341/0000950170-23-007341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023007341/life-20230310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:17:31.253262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}